Acute Myeloid Leukemia (AML) Overview

Save information for later
Sign Up

Learn About Acute Myeloid Leukemia (AML)

View Main Condition: Leukemia

What is the definition of Acute Myeloid Leukemia (AML)?
Acute myeloid leukemia (AML) is a cancer that affects the blood and bone marrow. Conditions are generally called "acute" when they develop quickly and have an aggressive course. The signs and symptoms of AML vary but may include easy bruising; bone pain or tenderness; fatigue; fever; frequent nosebleeds; bleeding from the gums; shortness of breath; and/or weightloss. AML is one of the most common types of leukemia among adults and is rarely diagnosed in people under age 40. There are many potential causes of AML such as certain blood disorders, inherited syndromes, environmental exposures, and drug exposures; however, most people who develop AML have no identifiable risk factor.
Who are the top Acute Myeloid Leukemia (AML) Local Doctors?
Dr. Olatoyosi M. Odenike
Hematology Oncology | Hematology | Oncology
Dr. Olatoyosi M. Odenike
Hematology Oncology | Hematology | Oncology

The University Of Chicago Medical Center

5841 S Maryland Ave, 
Chicago, IL 
 (8.9 mi)
773-702-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Olatoyosi Odenike is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Dr. Odenike and is rated as an Elite provider by MediFind in the treatment of Acute Myeloid Leukemia (AML). Her top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Myelofibrosis, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Odenike is currently accepting new patients.

Dr. Satyajit Kosuri
Hematology Oncology | Hematology | Oncology
Dr. Satyajit Kosuri
Hematology Oncology | Hematology | Oncology

The University Of Chicago Medical Center

5841 S Maryland Ave, 
Chicago, IL 
 (8.9 mi)
773-702-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Satyajit Kosuri is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Dr. Kosuri and is rated as a Distinguished provider by MediFind in the treatment of Acute Myeloid Leukemia (AML). His top areas of expertise are Acute Myeloid Leukemia (AML), Multiple Myeloma, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Kosuri is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Dr. Michael J. Thirman
Hematology Oncology | Hematology | Oncology
Dr. Michael J. Thirman
Hematology Oncology | Hematology | Oncology

University Of Chicago

5841 S Maryland Ave, 
Chicago, IL 
 (8.9 mi)
773-702-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Thirman is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Dr. Thirman and is rated as a Distinguished provider by MediFind in the treatment of Acute Myeloid Leukemia (AML). His top areas of expertise are Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML), Leukemia, and Bone Marrow Aspiration. Dr. Thirman is currently accepting new patients.

View All Doctors
What are the latest Acute Myeloid Leukemia (AML) Clinical Trials?
A Measurable Residual Disease (MRD) Driven, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients With Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial
A Measurable Residual Disease (MRD) Driven, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients With Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial
Enrollment Status: Recruiting
Publish Date: February 26, 2025
Intervention Type: Procedure, Drug
Study Phase: Phase 2

Summary: This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid leukemia (AML). Cytarabine is a drug that inhibits some of the enzymes needed for deoxyribonucleic acid (DNA) replication and repair and can slow or stop the gr...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who Are Considered High-Risk (Adverse) Acute Myeloid Leukemia As Determined by MYELOMATCH; A MYELOMATCH Clinical Trial
A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who Are Considered High-Risk (Adverse) Acute Myeloid Leukemia As Determined by MYELOMATCH; A MYELOMATCH Clinical Trial
Enrollment Status: Recruiting
Publish Date: February 26, 2025
Intervention Type: Procedure, Drug
Study Phase: Phase 2

Summary: This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome alone; 2) cytarabine and daunorubicin with venetoclax; 3) azacitidine and venetoclax; 4) daunorubicin and cytarabine li...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center